Compare NetEase Inc (NTES) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NetEase Inc vs Summit Therapeutics Inc — how do they compare? NetEase Inc trades at $124.24 (market cap $76.09B), while Summit Therapeutics Inc trades at $17.59 (market cap $13.71B). The key difference: NetEase Inc is far larger — about 5.5× Summit Therapeutics Inc's market cap, and NetEase Inc pays a 2.45% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold NetEase Inc for 73 Days and Summit Therapeutics Inc for 16 Days on average.
| NTES | SMMT | |
|---|---|---|
Market Cap | $76.09B | $13.71B |
Volume | 486,447 | 6,173,057 |
Sector | Technology | Health |
52-Week High | $152.85 | $26.38 |
52-Week Low | $109.26 | $12.43 |
Typical Hold Time | 73 Days | 16 Days |
Enterprise Value | $51.81B | $13.04B |
Dividend Yield | 2.45% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTES trades at $124.24, up 3.01% today, with a neutral technical signal and bearish moving averages. The stock shows strong fundamentals with a P/E of 15.92, net income margin of 27.88%, and robust cash flow from operations of $50.74 billion in 2025. Recent earnings were mixed, with a Q2 2026 miss but a Q1 2026 beat. Analyst consensus is strongly bullish with an $168 price target. News highlights focus on earnings results and long-term dividend growth potential.
The outlook for NTES is positive, supported by strong profitability, a healthy balance sheet, and analyst optimism. Key opportunities include revenue growth and AI investments, while risks involve earnings volatility and competitive pressures in the gaming sector. The stock presents a compelling case for growth investors seeking exposure to China's tech sector.
Summit Therapeutics (SMMT) trades at $17.59, down 2.01% on the day, amid mixed earnings performance but strong analyst support with a consensus price target of $29.33. The stock shows a bullish technical signal from moving averages, with key support at $17 and resistance at $18. Recent news highlights a major $2 billion strategic investment from AstraZeneca and expanded clinical collaborations, boosting investor optimism despite current negative profitability metrics.
The outlook for SMMT is heavily driven by clinical progress and partnerships, offering significant upside if drug trials succeed, but carries high risk due to substantial losses, negative cash flow from operations, and reliance on positive trial outcomes. Investors should weigh the potential rewards against the company's current financial health and execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NetEase Inc
NetEase, which started on an internet portal service in 1997, is a leading online services provider in China. Its key services include online/mobile games, cloud music, media, advertising, email, live streaming, online education, and e-commerce. The company develops and operates some of the China's most popular PC client and mobile games, and it partners with global leading game developers, such as Blizzard Entertainment and Mojang (a Microsoft subsidiary).
Read more on NTES →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
